RATIONALE: In schizophrenia patients, optimal treatment with antipsychotics requires weeks to months of sustained drug therapy. However, single administration of antipsychotic drugs can reverse schizophrenia-like behavioral alterations in rodent models of psychosis. This raises questions about the physiological relevance of such antipsychotic-like activity. OBJECTIVE: This study evaluates the effects of chronic treatment with clozapine on the cellular and behavioral responses induced by the hallucinogenic serotonin 5-HT(2A) receptor agonist lysergic acid diethylamide (LSD) as a mouse model of psychosis. METHOD: Mice were treated chronically (21 days) with 25 mg/kg/day clozapine. Experiments were conducted 1, 7, 14, and 21 days after the last clozapine administration. [(3)H]Ketanserin binding and 5-HT ( 2A ) mRNA expression were determined in mouse somatosensory cortex. Head-twitch behavior, expression of c-fos, which is induced by all 5-HT(2A) agonists, and expression of egr-1 and egr-2, which are LSD-like specific, were assayed. RESULTS: Head-twitch response was decreased and [(3)H]ketanserin binding was downregulated in 1, 7, and 14 days after chronic clozapine. 5-HT ( 2A ) mRNA was reduced 1 day after chronic clozapine. Induction of c-fos, but not egr-1 and egr-2, was rescued 7 days after chronic clozapine. These effects were not observed after short treatment (2 days) with clozapine or chronic haloperidol (1 mg/kg/day). CONCLUSION: Our findings provide a murine model of chronic atypical antipsychotic drug action and suggest downregulation of the 5-HT(2A) receptor as a potential mechanism involved in these persistent therapeutic-like effects.
RATIONALE: In schizophreniapatients, optimal treatment with antipsychotics requires weeks to months of sustained drug therapy. However, single administration of antipsychotic drugs can reverse schizophrenia-like behavioral alterations in rodent models of psychosis. This raises questions about the physiological relevance of such antipsychotic-like activity. OBJECTIVE: This study evaluates the effects of chronic treatment with clozapine on the cellular and behavioral responses induced by the hallucinogenic serotonin5-HT(2A) receptor agonist lysergic acid diethylamide (LSD) as a mouse model of psychosis. METHOD:Mice were treated chronically (21 days) with 25 mg/kg/day clozapine. Experiments were conducted 1, 7, 14, and 21 days after the last clozapine administration. [(3)H]Ketanserin binding and 5-HT ( 2A ) mRNA expression were determined in mouse somatosensory cortex. Head-twitch behavior, expression of c-fos, which is induced by all 5-HT(2A) agonists, and expression of egr-1 and egr-2, which are LSD-like specific, were assayed. RESULTS: Head-twitch response was decreased and [(3)H]ketanserin binding was downregulated in 1, 7, and 14 days after chronic clozapine. 5-HT ( 2A ) mRNA was reduced 1 day after chronic clozapine. Induction of c-fos, but not egr-1 and egr-2, was rescued 7 days after chronic clozapine. These effects were not observed after short treatment (2 days) with clozapine or chronic haloperidol (1 mg/kg/day). CONCLUSION: Our findings provide a murine model of chronic atypical antipsychotic drug action and suggest downregulation of the 5-HT(2A) receptor as a potential mechanism involved in these persistent therapeutic-like effects.
Authors: Javier González-Maeso; Tony Yuen; Barbara J Ebersole; Elisa Wurmbach; Alena Lira; Mingming Zhou; Noelia Weisstaub; Rene Hen; Jay A Gingrich; Stuart C Sealfon Journal: J Neurosci Date: 2003-10-01 Impact factor: 6.167
Authors: Mario de la Fuente Revenga; Daisuke Ibi; Justin M Saunders; Travis Cuddy; Maryum K Ijaz; Rudy Toneatti; Mitsumasa Kurita; Terrell Holloway; Li Shen; Jeremy Seto; Mikhail G Dozmorov; Javier González-Maeso Journal: Neuroscience Date: 2018-07-17 Impact factor: 3.590
Authors: Daisuke Ibi; Mario de la Fuente Revenga; Nebojsa Kezunovic; Carolina Muguruza; Justin M Saunders; Supriya A Gaitonde; José L Moreno; Maryum K Ijaz; Vishaka Santosh; Alexey Kozlenkov; Terrell Holloway; Jeremy Seto; Aintzane García-Bea; Mitsumasa Kurita; Grace E Mosley; Yan Jiang; Daniel J Christoffel; Luis F Callado; Scott J Russo; Stella Dracheva; Juan F López-Giménez; Yongchao Ge; Carlos R Escalante; J Javier Meana; Schahram Akbarian; George W Huntley; Javier González-Maeso Journal: Nat Neurosci Date: 2017-08-07 Impact factor: 24.884
Authors: Salvador Sierra; Karan H Muchhala; Donald K Jessup; Katherine M Contreras; Urjita H Shah; David L Stevens; Jennifer Jimenez; Xiomara K Cuno Lavilla; Mario de la Fuente Revenga; Kumiko M Lippold; Shanwei Shen; Justin L Poklis; Liya Y Qiao; William L Dewey; Hamid I Akbarali; M Imad Damaj; Javier González-Maeso Journal: Neuropharmacology Date: 2022-02-17 Impact factor: 5.273
Authors: Mitsumasa Kurita; José L Moreno; Terrell Holloway; Alexey Kozlenkov; Giuseppe Mocci; Aintzane García-Bea; James B Hanks; Rachael Neve; Eric J Nestler; Scott J Russo; Javier González-Maeso Journal: Mol Pharmacol Date: 2013-03-18 Impact factor: 4.436
Authors: Kelsey S Hideshima; Ashkhan Hojati; Justin M Saunders; Doan M On; Mario de la Fuente Revenga; Jong M Shin; Ana Sánchez-González; Cassandra M Dunn; Alexander B Pais; Anthony C Pais; Michael F Miles; Jennifer T Wolstenholme; Javier González-Maeso Journal: Psychopharmacology (Berl) Date: 2018-09-12 Impact factor: 4.530
Authors: Sally I Sharp; Ying Hu; Jon F Weymer; Mie Rizig; Andrew McQuillin; Stephen P Hunt; Hugh M D Gurling Journal: Psychiatr Genet Date: 2013-08 Impact factor: 2.458